Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:06:20.456Z.
Calculation as of: 2026-10-06T20:06:20.456Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d6bd3278d76725a85d4cb05495e45b99d0fd89b23371e3701c8289362793e8f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Design Therapeutics, Inc.
Market Cap
$747.61M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$753.02M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$761.37M
Price/FCF Ratio
14.40
TTM Avg
13.25
3Y Avg
14.26
5Y Avg
22.71
Market Cap
$723.18M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$721.69M
Price/FCF Ratio
N/A
TTM Avg
4.42
3Y Avg
4.41
5Y Avg
4.41
Market Cap
$777.34M
Price/FCF Ratio
N/A
TTM Avg
2.47
3Y Avg
2.47
5Y Avg
6.40
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $747.61M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 14.40 | 13.25 | 14.26 | 22.71 |
| Sana Biotechnology, Inc. (SANA)vs › | $765.30M | N/A | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | N/A | 4.42 | 4.41 | 4.41 |
| Geron Corporation (GERN)vs › | $776.24M | N/A | 60.32 | 60.32 | 60.32 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.34M | N/A | 2.47 | 2.47 | 6.40 |
| Varex Imaging Corporation (VREX)vs › | $778.01M | N/A | 16.85 | 20.13 | 24.20 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
